In Acerbic Tones, Ventana Rejects Roche's $3B Takeover Bid as 'Inadequate' | GenomeWeb
NEW YORK (GenomeWeb News) — Ventana Medical Systems’ board of directors has advised stockholders to reject Roche’s unsolicited, $3 billion bid to buy the company on the grounds that the $75-a-share offer is “inadequate in multiple respects and contrary to the best interests of Ventana’s stockholders,” the board stated this morning.
Ventana’s closing price on June 25 was $51.74 a share, the day Roche made its offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.